1. Market Research
  2. > Healthcare
  3. > Pathology Market Trends
  4. > Peripheral Neuropathy (Sensory Neuropathy) - Pipeline Review, H1 2016

Peripheral Neuropathy (Sensory Neuropathy) - Pipeline Review, H1 2016

  • February 2016
  • -
  • Global Markets Direct
  • -
  • 100 pages

Peripheral Neuropathy (Sensory Neuropathy) - Pipeline Review, H1 2016

Summary

Global Markets Direct’s, ‘Peripheral Neuropathy (Sensory Neuropathy) - Pipeline Review, H1 2016’, provides an overview of the Peripheral Neuropathy (Sensory Neuropathy) pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Peripheral Neuropathy (Sensory Neuropathy), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Peripheral Neuropathy (Sensory Neuropathy) and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.


Scope

- The report provides a snapshot of the global therapeutic landscape of Peripheral Neuropathy (Sensory Neuropathy)
- The report reviews pipeline therapeutics for Peripheral Neuropathy (Sensory Neuropathy) by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Peripheral Neuropathy (Sensory Neuropathy) therapeutics and enlists all their major and minor projects
- The report assesses Peripheral Neuropathy (Sensory Neuropathy) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Peripheral Neuropathy (Sensory Neuropathy)

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Peripheral Neuropathy (Sensory Neuropathy)
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Peripheral Neuropathy (Sensory Neuropathy) pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table Of Contents

Peripheral Neuropathy (Sensory Neuropathy) - Pipeline Review, H1 2016
Table of Contents
Table of Contents 2
List of Tables 6
List of Figures 7
Introduction 8
Global Markets Direct Report Coverage 8
Peripheral Neuropathy (Sensory Neuropathy) Overview 9
Therapeutics Development 10
Pipeline Products for Peripheral Neuropathy (Sensory Neuropathy) - Overview 10
Pipeline Products for Peripheral Neuropathy (Sensory Neuropathy) - Comparative Analysis 11
Peripheral Neuropathy (Sensory Neuropathy) - Therapeutics under Development by Companies 12
Peripheral Neuropathy (Sensory Neuropathy) - Therapeutics under Investigation by Universities/Institutes 14
Peripheral Neuropathy (Sensory Neuropathy) - Pipeline Products Glance 15
Late Stage Products 15
Clinical Stage Products 16
Early Stage Products 17
Unknown Stage Products 18
Peripheral Neuropathy (Sensory Neuropathy) - Products under Development by Companies 19
Peripheral Neuropathy (Sensory Neuropathy) - Products under Investigation by Universities/Institutes 20
Peripheral Neuropathy (Sensory Neuropathy) - Companies Involved in Therapeutics Development 21
Araim Pharmaceuticals, Inc. 21
Arcturus Therapeutics, Inc 22
aTyr Pharma, Inc. 23
Baxalta Incorporated 24
CSL Limited 25
GeNeuro SA 26
INSYS Therapeutics, Inc. 27
Mitsubishi Tanabe Pharma Corporation 28
Neuren Pharmaceuticals Limited 29
Neurocentrx Pharma Ltd. 30
Pfizer Inc. 31
Polyneuron Pharmaceuticals AG 32
RegeneRx Biopharmaceuticals, Inc. 33
Sanofi 34
Teijin Pharma Limited 35
Peripheral Neuropathy (Sensory Neuropathy) - Therapeutics Assessment 36
Assessment by Monotherapy Products 36
Assessment by Combination Products 37
Assessment by Target 38
Assessment by Mechanism of Action 40
Assessment by Route of Administration 42
Assessment by Molecule Type 44
Drug Profiles 46
(immune globulin (human) + hyaluronidase (recombinant)) - Drug Profile 46
Product Description 46
Mechanism of Action 46
RandD Progress 46
aminoquinol - Drug Profile 48
Product Description 48
Mechanism of Action 48
RandD Progress 48
Cannabidiol - Drug Profile 49
Product Description 49
Mechanism of Action 49
RandD Progress 49
cibinetide - Drug Profile 51
Product Description 51
Mechanism of Action 51
RandD Progress 51
Drugs for Peripheral Neuropathy - Drug Profile 54
Product Description 54
Mechanism of Action 54
RandD Progress 54
fingolimod hydrochloride - Drug Profile 55
Product Description 55
Mechanism of Action 55
RandD Progress 55
GL-2045 - Drug Profile 58
Product Description 58
Mechanism of Action 58
RandD Progress 58
GNbAC-1 - Drug Profile 59
Product Description 59
Mechanism of Action 59
RandD Progress 59
immune globulin (human) - Drug Profile 61
Product Description 61
Mechanism of Action 61
RandD Progress 61
immune globulin (human) - Drug Profile 62
Product Description 62
Mechanism of Action 62
RandD Progress 62
immune globulin (human) - Drug Profile 65
Product Description 65
Mechanism of Action 65
RandD Progress 65
LUNAR-102 - Drug Profile 66
Product Description 66
Mechanism of Action 66
RandD Progress 66
NNZ-2591 - Drug Profile 67
Product Description 67
Mechanism of Action 67
RandD Progress 67
Peptide to Activate GLP1R for CNS, Metabolic Disorders and Head Trauma - Drug Profile 68
Product Description 68
Mechanism of Action 68
RandD Progress 68
Peptides to Activate GLP-1 Receptor for CNS Disorders and Head Trauma - Drug Profile 70
Product Description 70
Mechanism of Action 70
RandD Progress 70
pirenzepine hydrochloride - Drug Profile 71
Product Description 71
Mechanism of Action 71
RandD Progress 71
PN-1007 - Drug Profile 72
Product Description 72
Mechanism of Action 72
RandD Progress 72
Proteins for Inflammation, Hematological, Metabolic, Oncology, Neurodegenerative and Cardiovascular Disorder - Drug Profile 73
Product Description 73
Mechanism of Action 73
RandD Progress 73
RGN-352 - Drug Profile 74
Product Description 74
Mechanism of Action 74
RandD Progress 74
SAR-184841 - Drug Profile 76
Product Description 76
Mechanism of Action 76
RandD Progress 76
Synthetic Peptides for Peripheral Neuropathy - Drug Profile 77
Product Description 77
Mechanism of Action 77
RandD Progress 77
Peripheral Neuropathy (Sensory Neuropathy) - Recent Pipeline Updates 78
Peripheral Neuropathy (Sensory Neuropathy) - Dormant Projects 91
Peripheral Neuropathy (Sensory Neuropathy) - Discontinued Products 93
Peripheral Neuropathy (Sensory Neuropathy) - Product Development Milestones 94
Featured News and Press Releases 94
Aug 10, 2015: Gliknik Licensee Pfizer Receives Orphan Drug Designation From U.S. Food and Drug Administration for Drug Candidate Directed Towards Rare Neurological Disorder 94
Jul 12, 2013: Neuren Receives Notice of Allowance for New Patent 94
Apr 04, 2013: CSL Behring's Privigen Obtains European Approval For Treatment Of Chronic Inflammatory Demyelinating Polyneuropathy 94
Feb 21, 2013: CHMP Adopts Positive Opinion Recommending Variation To Terms Of Marketing Authorization For CSL Behring's Privigen 95
Jun 27, 2012: PRIMA Study Shows Treatment With Privigen Improved Function In Patients With Chronic Inflammatory Demyelinating Polyneuropathy 96
May 30, 2012: CSL Behring Submits Marketing Authorization Variation Application To EMA For Privigen In Chronic Inflammatory Demyelinating Polyradiculoneuropathy 97
Mar 26, 2012: CSL Behring Enrolls First Patient In PATH Trial To Evaluate Hizentra For Treatment Of CIDP 97
Appendix 99
Methodology 99
Coverage 99
Secondary Research 99
Primary Research 99
Expert Panel Validation 99
Contact Us 99
Disclaimer 100

List of Tables
Number of Products under Development for Peripheral Neuropathy (Sensory Neuropathy), H1 2016 10
Number of Products under Development for Peripheral Neuropathy (Sensory Neuropathy) - Comparative Analysis, H1 2016 11
Number of Products under Development by Companies, H1 2016 13
Number of Products under Investigation by Universities/Institutes, H1 2016 14
Comparative Analysis by Late Stage Development, H1 2016 15
Comparative Analysis by Clinical Stage Development, H1 2016 16
Comparative Analysis by Early Stage Development, H1 2016 17
Comparative Analysis by Unknown Stage Development, H1 2016 18
Products under Development by Companies, H1 2016 19
Products under Investigation by Universities/Institutes, H1 2016 20
Peripheral Neuropathy (Sensory Neuropathy) - Pipeline by Araim Pharmaceuticals, Inc., H1 2016 21
Peripheral Neuropathy (Sensory Neuropathy) - Pipeline by Arcturus Therapeutics, Inc, H1 2016 22
Peripheral Neuropathy (Sensory Neuropathy) - Pipeline by aTyr Pharma, Inc., H1 2016 23
Peripheral Neuropathy (Sensory Neuropathy) - Pipeline by Baxalta Incorporated, H1 2016 24
Peripheral Neuropathy (Sensory Neuropathy) - Pipeline by CSL Limited, H1 2016 25
Peripheral Neuropathy (Sensory Neuropathy) - Pipeline by GeNeuro SA, H1 2016 26
Peripheral Neuropathy (Sensory Neuropathy) - Pipeline by INSYS Therapeutics, Inc., H1 2016 27
Peripheral Neuropathy (Sensory Neuropathy) - Pipeline by Mitsubishi Tanabe Pharma Corporation, H1 2016 28
Peripheral Neuropathy (Sensory Neuropathy) - Pipeline by Neuren Pharmaceuticals Limited, H1 2016 29
Peripheral Neuropathy (Sensory Neuropathy) - Pipeline by Neurocentrx Pharma Ltd., H1 2016 30
Peripheral Neuropathy (Sensory Neuropathy) - Pipeline by Pfizer Inc., H1 2016 31
Peripheral Neuropathy (Sensory Neuropathy) - Pipeline by Polyneuron Pharmaceuticals AG, H1 2016 32
Peripheral Neuropathy (Sensory Neuropathy) - Pipeline by RegeneRx Biopharmaceuticals, Inc., H1 2016 33
Peripheral Neuropathy (Sensory Neuropathy) - Pipeline by Sanofi, H1 2016 34
Peripheral Neuropathy (Sensory Neuropathy) - Pipeline by Teijin Pharma Limited, H1 2016 35
Assessment by Monotherapy Products, H1 2016 36
Assessment by Combination Products, H1 2016 37
Number of Products by Stage and Target, H1 2016 39
Number of Products by Stage and Mechanism of Action, H1 2016 41
Number of Products by Stage and Route of Administration, H1 2016 43
Number of Products by Stage and Molecule Type, H1 2016 45
Peripheral Neuropathy (Sensory Neuropathy) Therapeutics - Recent Pipeline Updates, H1 2016 78
Peripheral Neuropathy (Sensory Neuropathy) - Dormant Projects, H1 2016 91
Peripheral Neuropathy (Sensory Neuropathy) - Dormant Projects (Contd..1), H1 2016 92
Peripheral Neuropathy (Sensory Neuropathy) - Discontinued Products, H1 2016 93

List of Figures
Number of Products under Development for Peripheral Neuropathy (Sensory Neuropathy), H1 2016 10
Number of Products under Development for Peripheral Neuropathy (Sensory Neuropathy) - Comparative Analysis, H1 2016 11
Number of Products under Development by Companies, H1 2016 12
Comparative Analysis by Clinical Stage Development, H1 2016 16
Comparative Analysis by Early Stage Products, H1 2016 17
Assessment by Monotherapy Products, H1 2016 36
Number of Products by Targets, H1 2016 38
Number of Products by Stage and Targets, H1 2016 38
Number of Products by Mechanism of Actions, H1 2016 40
Number of Products by Stage and Mechanism of Actions, H1 2016 40
Number of Products by Routes of Administration, H1 2016 42
Number of Products by Stage and Top 10 Routes of Administration, H1 2016 42
Number of Products by Top 10 Molecule Types, H1 2016 44
Number of Products by Stage and Top 10 Molecule Types, H1 2016 44

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
Potassium Voltage Gated Channel Subfamily KQT Member 3 (Potassium Channel Subunit Alpha KvLQT3 or Voltage Gated Potassium Channel Subunit Kv7.3 or KCNQ3) - Pipeline Review, H2 2016

Potassium Voltage Gated Channel Subfamily KQT Member 3 (Potassium Channel Subunit Alpha KvLQT3 or Voltage Gated Potassium Channel Subunit Kv7.3 or KCNQ3) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • August 2016
  • by Global Markets Direct

Potassium Voltage Gated Channel Subfamily KQT Member 3 (Potassium Channel Subunit Alpha KvLQT3 or Voltage Gated Potassium Channel Subunit Kv7.3 or KCNQ3) - Pipeline Review, H2 2016 Summary Global Markets ...

Nuclear Factor Erythroid 2 Related Factor 2 (HEBP1 or Nuclear Factor Erythroid Derived 2 Like 2 or NFE2L2) - Pipeline Review, H2 2016

Nuclear Factor Erythroid 2 Related Factor 2 (HEBP1 or Nuclear Factor Erythroid Derived 2 Like 2 or NFE2L2) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • August 2016
  • by Global Markets Direct

Nuclear Factor Erythroid 2 Related Factor 2 (HEBP1 or Nuclear Factor Erythroid Derived 2 Like 2 or NFE2L2) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Nuclear Factor Erythroid 2 Related ...

Dystrophin (DMD) - Pipeline Review, H2 2016

Dystrophin (DMD) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • August 2016
  • by Global Markets Direct

Dystrophin (DMD) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Dystrophin (DMD) - Pipeline Review, H2 2016’, provides in depth analysis on Dystrophin (DMD) targeted pipeline therapeutics. ...


ref:plp2016

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.